Quick Allison M, McLaughlin Eric, Krok Schoen Jessica L, Felix Ashley S, Presley Carolyn J, Cespedes Feliciano Elizabeth M, Shadyab Aladdin H, Jung Su Yon, Luo Juhua, King Jennifer J, Rapp Stephen R, Werts Samantha, Chlebowski Rowan T, Naughton Michelle, Paskett Electra
Department of Radiation Oncology, The Ohio State University Medical Center, Columbus, OH, USA.
Center for Biostatistics, The Ohio State University, The Ohio State University, Columbus, OH, USA.
J Cancer Surviv. 2025 Feb;19(1):206-215. doi: 10.1007/s11764-023-01460-8. Epub 2023 Sep 5.
To evaluate changes in physical function (PF) for older women with endometrial cancer (EC) + / - adjuvant therapy in the Women's Health Initiative Life and Longevity after Cancer cohort.
This study examined women ≥ 70 years of age with EC with available treatment records. Change in PF was measured using the RAND-36 and compared between groups using Wilcoxon rank-sum tests. Multivariable median regression was used to compare the changes in scores while adjusting for confounding variables.
Included in the study were 287 women, 150 (52.3%) women who did not receive adjuvant therapy and 137 (47.7%) who received adjuvant therapy. When comparing PF scores, there was a statistically significant difference in the median percent change in functional decline, with a greater decline in those who received adjuvant therapy (- 5.9% [- 23.5 to 0%]) compared to those who did not (0 [- 18.8 to + 6.7%]), p = 0.02). Results were not statistically significant after multivariable adjustment, but women who underwent chemotherapy had a greater percent change (median ∆ - 13.8% [- 35.5 to 0%]) compared to those who received radiation alone (median ∆ - 5.9% [- 31.3 to 0%]) or chemotherapy and radiation (median ∆ - 6.5% [- 25.8 to + 5.7%].
Older women with EC who received adjuvant therapy experienced greater change in PF than those who did not receive adjuvant therapy, particularly women who received chemotherapy. These results were not statistically significant on multivariate analysis.
EC survivors may experience changes in PF because of chemotherapy and/or radiation therapy. Additional supportive care may need to be provided to older women to mitigate functional decline.
在女性健康倡议癌症队列研究的癌症后生活与长寿项目中,评估接受或未接受辅助治疗的老年子宫内膜癌(EC)女性的身体功能(PF)变化。
本研究调查了年龄≥70岁且有可用治疗记录的EC女性。使用RAND-36量表测量PF变化,并通过Wilcoxon秩和检验在组间进行比较。采用多变量中位数回归在调整混杂变量的同时比较得分变化。
该研究纳入了287名女性,其中150名(52.3%)未接受辅助治疗,137名(47.7%)接受了辅助治疗。比较PF得分时,功能下降的中位数百分比变化存在统计学显著差异,接受辅助治疗的女性(-5.9%[-23.5%至0%])比未接受辅助治疗的女性(0[-18.8%至+6.7%])下降幅度更大,p = 0.02)。多变量调整后结果无统计学显著性,但接受化疗的女性百分比变化更大(中位数变化-13.8%[-35.5%至0%]),相比仅接受放疗的女性(中位数变化-5.9%[-31.3%至0%])或接受化疗和放疗的女性(中位数变化-6.5%[-25.8%至+5.7%])。
接受辅助治疗的老年EC女性比未接受辅助治疗的女性PF变化更大,尤其是接受化疗的女性。这些结果在多变量分析中无统计学显著性。
EC幸存者可能因化疗和/或放疗而出现PF变化。可能需要为老年女性提供额外的支持性护理以减轻功能下降。